Simple Summary Pancreatic cancer is difficult to treat. Novel treatment strategies are
urgently needed to improve the survival rate, which is approximately 10% five years after …

Pancreatic cancer is one of the most malignant tumors with one of the worst survival rates
due to its insidious onset and resistance to therapies. Most therapeutics show a desired …

Currently, pancreatic cancer (PC) is one of the most lethal malignant tumors. PC is typically
diagnosed at a late stage, exhibits a poor response to conventional treatment, and has a …

Pancreatic cancer is known for its dismal prognosis despite efforts to improve therapeutic
outcome. Recently, cancer nanomedicine, application of nanotechnology to cancer …

Since the advent of nanomedicine, physicians have harnessed these approaches for the
prophylaxis, detection, and therapy of life-threatening diseases, particularly cancer …

Pancreatic cancer is one of the most lethal malignant tumors with a low survival rate, partly
because the tumor microenvironment (TME), which consists of extracellular matrix (ECM) …

Simple Summary The poor prognosis and survival rates associated with pancreatic cancer
show that there is a clear unmet need for better disease management. The heterogeneity of …

Simple Summary Despite access to a vast arsenal of anticancer agents, many fail to realise
their full therapeutic potential in clinical practice. One key determinant of this is the evolution …

Despite significant developments in cancer treatment, the median survival after diagnosis
still ranges between 2 and 8 months; the 5-year survival rate is less than 5%, and thus early …

While chemotherapy is the only approved non-surgical option for the majority of pancreatic
cancer patients, it rarely results in a cure. The failure to respond to chemotherapy is due to …